THE “DARK SIDE” OF DEEP VEIN THROMBOSIS - CASE REPORT

Authors

  • Irina Iuliana COSTACHE University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • Ana-Maria BUBURUZ University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • V. FOTEA University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • A. COZMA University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi
  • Viviana AURSULESEI University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

Abstract

Venous thromboembolism (VTE) is an increasingly common cause of morbidity and mortality in cancer patients. In various malignancies the incidence of thrombosis ranges from 5% to 60%, that is four times higher in cancer patients compared to the general population. Large retrospective studies have shown that in men the tumors which are most commonly associated with VTE are lung cancer and pancreatic cancer and, in women cancer of the genital area, pancreas, colon and rectum. Thromboembolic events may often occur before the cancer diagnosis. We present the case of a 41year-old female patient with a history of genital cancer which was surgically treated and who is now admitted for clinical signs of ileofemoral deep vein thrombosis (DVT) of the left leg. The diagnosis was confirmed by laboratory data and Doppler ultrasound and the patient received anticoagulant treatment. Given the history of the patient, abdominal and pelvic ultrasound and computer tomography (CT) were performed to detect the cause who predisposed to the thrombotic event. These confirmed the ovarian cancer, this time on the right side, and the presence of hepatic and pulmonary metastasis. This case highlights the importance of screening for a cause of the thromboembolic event in patients, especially in those who have a history of a neoplasia.

Author Biographies

  • Irina Iuliana COSTACHE, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Medical Specialties (I)

  • Ana-Maria BUBURUZ, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Medical Specialties (I)

  • V. FOTEA, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Surgery

  • A. COZMA, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Medical Specialties (I)

  • Viviana AURSULESEI, University of Medicine and Pharmacy “Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Medical Specialties (I)

References

1. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel-Dieu Paris 1865; 3: 654–712.
2. Dumitraşcu D. Tromboza periferică paraneoplazică: ce este clasic şi ce este actual? Rev Soc Med Int 2010; 0(3): 49-55.
3. Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost. 2015; 13(8): 1372-1382.
4. García Escobar I, Antonio Rebollo M, García Adrián S et al. Safety and efficacy of primary thrombo-prophylaxis in cancer patients. Clin Transl Oncol 2016; 18: 1-11.
5. F. Mitu, Leon MM, Mitu M. Upper-extremity deep vein thrombosis: current concepts in diagnosis and treatment. Rev Med Chir Soc Med Iasi 2011; 115(2): 316-324.
6. Ho P, Lim HY, Chua CC et al. Retrospective review on isolated distal deep vein thrombosis (IDDVT) - A benign entity or not? Thromb Res 2016; 142: 11-16.
7. Ye S, Zhang W, Yang J et al. Pattern of venous thromboembolism occurrence in gynecologic malig-nancy: incidence, timing, and distribution a 10-year retrospective single-institutional study. Medicine (Baltimore) 2015; 94(50): e2316.
8. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochem 1985; 24: 5558-5567.
9. Gordon SG, Mielicki WP. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8: 73-86.
10. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11: 249–266.
11. Gordon SG, Mielicki WP. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8: 73-86.
12. Monreal M, Lensing AW, Prins MH et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2: 876-881.
13. Apras S, Elsurer R, Calguneri M et al. Massive deep venous thrombosis and venous gangrene in a 29-year-old case: metastatic epidermoid carcinoma with an unknown primary. Hematology 2004; 9(4): 297-300.
14. Madabhavi I, Patel A, Choudhary M, Anand A. Paraneoplastic internal jugular vein thrombosis leading to diagnosis of bilateral ovarian ependymoma. Case Rep Obstet Gynecol 2014; 2014: 324509. doi: 10.1155/2014/324509.
15. Shiota M, Kotani Y, Umemoto M et al. Risk factors for deep-vein thrombosis and pulmonary throm-boembolism in benign ovarian tumor. Tohoku J Exp Med 2011; 225(1): 1-3.
16. Asciutto G, Mumme A, Marpe B et al. Acute iliofemoral deep venous thrombosis due to gi-ant ovarian tumor: report of a hybrid treatment. Vasa 2008; 37(3): 278-280.
17. Haliga R, Drug VL, Negru D, Ambarus V, Neghina I, Sorodoc L. Unmasking a young adult migrato-ry deep venous thrombosis-case report. Rev Med Chir Soc Med Nat Iasi 2013; 117(4): 924-928.
18. Berrah-Bennaceur M, Berrah A, Arrada M. Venous thrombosis and cancer: about an Algerian series. Thromb Res 2016; 140(Suppl 1): S179-S182.
19. Dentali F, Pegoraro S., Barco S. et al. Clinical history of cancer patients with isolated distal deep vein thrombosis: a multicenter cohort study. Thromb Res 2016; 140(Suppl 1): S168-S171.
20. Bakhru A. Effect of ovarian tumor characteristics on venous thromboembolic risk. J Gynecol On-col 2013; 24(1): 52-58.

Additional Files

Published

2016-06-30

Issue

Section

INTERNAL MEDICINE - PEDIATRICS